{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,19]],"date-time":"2026-04-19T22:23:07Z","timestamp":1776637387856,"version":"3.51.2"},"reference-count":70,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2017,7,24]],"date-time":"2017-07-24T00:00:00Z","timestamp":1500854400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","award":["602604"],"award-info":[{"award-number":["602604"]}],"id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,9,7]]},"abstract":"<jats:title>Summary<\/jats:title>\n               <jats:p>Because of the high variability of seasonal influenza viruses and the eminent threat of influenza viruses with pandemic potential, there is great interest in the development of vaccines that induce broadly protective immunity. Most probably, broadly protective influenza vaccines are based on conserved proteins, such as nucleoprotein (NP). NP is a vaccine target of interest as it has been shown to induce cross-reactive antibody and T cell responses. Here we tested and compared various NP-based vaccine preparations for their capacity to induce humoral and cellular immune responses to influenza virus NP. The immunogenicity of protein-based vaccine preparations with Matrix-M\u2122 adjuvant as well as recombinant viral vaccine vector modified Vaccinia virus Ankara (MVA) expressing the influenza virus NP gene, with or without modifications that aim at optimization of CD8+ T cell responses, was addressed in BALB\/c mice. Addition of Matrix-M\u2122 adjuvant to NP wild-type protein-based vaccines significantly improved T cell responses. Furthermore, recombinant MVA expressing the influenza virus NP induced strong antibody and CD8+ T cell responses, which could not be improved further by modifications of NP to increase antigen processing and presentation.<\/jats:p>","DOI":"10.1111\/cei.13004","type":"journal-article","created":{"date-parts":[[2017,6,30]],"date-time":"2017-06-30T15:16:39Z","timestamp":1498835799000},"page":"19-28","source":"Crossref","is-referenced-by-count":8,"title":["Protein and modified vaccinia virus Ankara-based influenza virus nucleoprotein vaccines are differentially immunogenic in BALB\/c mice"],"prefix":"10.1093","volume":"190","author":[{"given":"A F","family":"Altenburg","sequence":"first","affiliation":[{"name":"Department of Viroscience, Postgraduate School of Molecular Medicine, Erasmus MC, Rotterdam, the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S E","family":"Magnusson","sequence":"additional","affiliation":[{"name":"Novavax AB, Uppsala, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F","family":"Bosman","sequence":"additional","affiliation":[{"name":"AmatsiQ-Biologicals, Ghent, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L","family":"Stertman","sequence":"additional","affiliation":[{"name":"Novavax AB, Uppsala, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R D","family":"de Vries","sequence":"additional","affiliation":[{"name":"Department of Viroscience, Postgraduate School of Molecular Medicine, Erasmus MC, Rotterdam, the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1921-4581","authenticated-orcid":false,"given":"G F","family":"Rimmelzwaan","sequence":"additional","affiliation":[{"name":"Department of Viroscience, Postgraduate School of Molecular Medicine, Erasmus MC, Rotterdam, the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2017,7,24]]},"reference":[{"key":"2021120808191529000_cei13004-bib-0001","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1126\/science.1244730","article-title":"Substitutions near the receptor binding site determine major antigenic change during influenza virus evolution","volume":"342","author":"Koel","year":"2013","journal-title":"Science"},{"key":"2021120808191529000_cei13004-bib-0002","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1099\/vir.0.043059-0","article-title":"Genetic evolution of the neuraminidase of influenza A (H3N2) viruses from 1968 to 2009 and its correspondence to haemagglutinin evolution","volume":"93","author":"Westgeest","year":"2012","journal-title":"J Gen Virol"},{"key":"2021120808191529000_cei13004-bib-0003","first-page":"1186","volume-title":"Field's virology","author":"Wright","year":"2013","edition":"6th"},{"key":"2021120808191529000_cei13004-bib-0004","author":"World Health Organization (WHO)"},{"key":"2021120808191529000_cei13004-bib-0005","author":"World Health Organization (WHO)"},{"key":"2021120808191529000_cei13004-bib-0006","volume-title":"Human infection with avian influenza A(H7N9) virus in China","author":"World Health Organization (WHO)"},{"key":"2021120808191529000_cei13004-bib-0007","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2807\/1560-7917.ES2015.20.4.21022","article-title":"Interim estimates of 2014\/15 vaccine effectiveness against influenza A(H3N2) from Canada's Sentinel Physician Surveillance Network, January 2015","volume":"20","author":"Skowronski","year":"2015","journal-title":"Euro Surveill"},{"key":"2021120808191529000_cei13004-bib-0008","first-page":"21025","article-title":"Low effectiveness of seasonal influenza vaccine in preventing laboratory-confirmed influenza in primary care in the United Kingdom: 2014\/15 mid-season results","volume":"20","author":"Pebody","year":"2015","journal-title":"Euro Surveill"},{"key":"2021120808191529000_cei13004-bib-0009","first-page":"10","article-title":"Early estimates of seasonal influenza vaccine effectiveness \u2013 United States, January 2015","volume":"64","author":"Flannery","year":"2015","journal-title":"Morb Mortal Wkly Rep"},{"key":"2021120808191529000_cei13004-bib-0010","volume-title":"Recommended composition of influenza virus vaccines for the use in the 2017\u20132018 northern hemisphere influenza season","author":"World Health Organization (WHO)"},{"key":"2021120808191529000_cei13004-bib-0011","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.vaccine.2014.11.054","article-title":"Virus-specific T cells as correlate of (cross-) protective immunity against influenza","volume":"33","author":"Altenburg","year":"2015","journal-title":"Vaccine"},{"key":"2021120808191529000_cei13004-bib-0012","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1038\/nm.3350","article-title":"Cellular immune correlates of protection against symptomatic pandemic influenza","volume":"19","author":"Sridhar","year":"2013","journal-title":"Nat Med"},{"key":"2021120808191529000_cei13004-bib-0013","doi-asserted-by":"crossref","first-page":"11756","DOI":"10.1128\/JVI.01460-06","article-title":"Cellular immune responses in children and adults receiving inactivated or live attenuated influenza vaccines","volume":"80","author":"He","year":"2006","journal-title":"J Virol"},{"key":"2021120808191529000_cei13004-bib-0014","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1128\/CVI.00397-07","article-title":"Correlation of cellular immune responses with protection against culture-confirmed influenza virus in young children","volume":"15","author":"Forrest","year":"2008","journal-title":"Clin Vaccine Immunol"},{"key":"2021120808191529000_cei13004-bib-0015","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1084\/jem.175.4.1143","article-title":"Transgenic mice lacking class I major histocompatibility complex-restricted T cells have delayed viral clearance and increased mortality after influenza virus challenge","volume":"175","author":"Bender","year":"1992","journal-title":"J Exp Med"},{"key":"2021120808191529000_cei13004-bib-0016","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1172\/JCI41902","article-title":"Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine","volume":"120","author":"Corti","year":"2010","journal-title":"J Clin Invest"},{"key":"2021120808191529000_cei13004-bib-0017","doi-asserted-by":"crossref","first-page":"e3942","DOI":"10.1371\/journal.pone.0003942","article-title":"Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells","volume":"3","author":"Throsby","year":"2008","journal-title":"PLOS ONE"},{"key":"2021120808191529000_cei13004-bib-0018","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1126\/science.1171491","article-title":"Antibody recognition of a highly conserved influenza virus epitope","volume":"324","author":"Ekiert","year":"2009","journal-title":"Science"},{"key":"2021120808191529000_cei13004-bib-0019","doi-asserted-by":"crossref","first-page":"10435","DOI":"10.1128\/JVI.01715-13","article-title":"Hemagglutinin stalk-based universal vaccine constructs protect against group 2 influenza A viruses","volume":"87","author":"Margine","year":"2013","journal-title":"J Virol"},{"key":"2021120808191529000_cei13004-bib-0020","doi-asserted-by":"crossref","first-page":"13133","DOI":"10.1073\/pnas.1414070111","article-title":"Induction of broadly cross-reactive antibody responses to the influenza HA stem region following H5N1 vaccination in humans","volume":"111","author":"Ellebedy","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"key":"2021120808191529000_cei13004-bib-0021","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1586\/14760584.2015.1060860","article-title":"Universal influenza vaccines, science fiction or soon reality?","volume":"14","author":"de Vries","year":"2015","journal-title":"Expert Rev Vaccines"},{"key":"2021120808191529000_cei13004-bib-0022","first-page":"301","article-title":"Advances in universal influenza virus vaccine design and antibody mediated therapies based on conserved regions of the hemagglutinin","volume":"386","author":"Krammer","year":"2015","journal-title":"Curr Top Microbiol Immunol"},{"key":"2021120808191529000_cei13004-bib-0023","doi-asserted-by":"crossref","first-page":"S120","DOI":"10.1016\/j.cmi.2015.12.005","article-title":"Universal influenza vaccines: a realistic option?","volume":"22","author":"de Vries","year":"2016","journal-title":"Clin Microbiol Infect"},{"key":"2021120808191529000_cei13004-bib-0024","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.3390\/v6072735","article-title":"Modified vaccinia virus Ankara (MVA) as production platform for vaccines against influenza and other viral respiratory diseases","volume":"6","author":"Altenburg","year":"2014","journal-title":"Viruses"},{"key":"2021120808191529000_cei13004-bib-0025","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.1080\/21645515.2016.1210729","article-title":"Viral vector-based influenza vaccines","volume":"12","author":"de Vries","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"2021120808191529000_cei13004-bib-0026","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1055\/s-0028-1108143","article-title":"[MVA vaccination against smallpox: clinical tests with an attenuated live vaccinia virus strain (MVA) (author's translation)]","volume":"99","author":"Stickl","year":"1974","journal-title":"Dtsch Med Wochenschr"},{"key":"2021120808191529000_cei13004-bib-0027","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.1016\/j.vaccine.2012.02.016","article-title":"Biosafety aspects of modified vaccinia virus Ankara (MVA)-based vectors used for gene therapy or vaccination","volume":"30","author":"Verheust","year":"2012","journal-title":"Vaccine"},{"key":"2021120808191529000_cei13004-bib-0028","doi-asserted-by":"crossref","first-page":"6436","DOI":"10.1016\/j.vaccine.2016.06.059","article-title":"Vector-based genetically modified vaccines: exploiting Jenner's legacy","volume":"34","author":"Ramezanpour","year":"2016","journal-title":"Vaccine"},{"key":"2021120808191529000_cei13004-bib-0029","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1046\/j.1365-2567.2003.01738.x","article-title":"The MHC class I antigen presentation pathway: strategies for viral immune evasion","volume":"110","author":"Hewitt","year":"2003","journal-title":"Immunology"},{"key":"2021120808191529000_cei13004-bib-0030","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1016\/0264-410X(95)00089-J","article-title":"Enhancement of humoral response against human influenza vaccine with the simple submicron oil\/water emulsion adjuvant MF59","volume":"13","author":"Ott","year":"1995","journal-title":"Vaccine"},{"key":"2021120808191529000_cei13004-bib-0031","doi-asserted-by":"crossref","first-page":"7367","DOI":"10.1016\/j.vaccine.2009.09.044","article-title":"Intramuscular Matrix-M-adjuvanted virosomal H5N1 vaccine induces high frequencies of multifunctional Th1 CD4+ cells and strong antibody responses in mice","volume":"27","author":"Madhun","year":"2009","journal-title":"Vaccine"},{"key":"2021120808191529000_cei13004-bib-0032","doi-asserted-by":"crossref","first-page":"8049","DOI":"10.1016\/j.vaccine.2011.08.042","article-title":"Evaluation of a virosomal H5N1 vaccine formulated with Matrix M adjuvant in a phase I clinical trial","volume":"29","author":"Cox","year":"2011","journal-title":"Vaccine"},{"key":"2021120808191529000_cei13004-bib-0033","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1111\/j.1750-2659.2011.00256.x","article-title":"Matrix-M adjuvanted virosomal H5N1 vaccine confers protection against lethal viral challenge in a murine model","volume":"5","author":"Pedersen","year":"2011","journal-title":"Influenza Other Respir Viruses"},{"key":"2021120808191529000_cei13004-bib-0034","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1016\/j.vaccine.2013.01.039","article-title":"Immune enhancing properties of the novel Matrix-M adjuvant leads to potentiated immune responses to an influenza vaccine in mice","volume":"31","author":"Magnusson","year":"2013","journal-title":"Vaccine"},{"key":"2021120808191529000_cei13004-bib-0035","doi-asserted-by":"crossref","first-page":"e0145243","DOI":"10.1371\/journal.pone.0145243","article-title":"Protection against H5N1 influenza virus induced by Matrix-M adjuvanted seasonal virosomal vaccine in mice requires both antibodies and T cells","volume":"10","author":"Cox","year":"2015","journal-title":"PLOS ONE"},{"key":"2021120808191529000_cei13004-bib-0036","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/mi.2008.59","article-title":"Pulmonary delivery of ISCOMATRIX influenza vaccine induces both systemic and mucosal immunity with antigen dose sparing","volume":"1","author":"Wee","year":"2008","journal-title":"Mucosal Immunol"},{"key":"2021120808191529000_cei13004-bib-0037","doi-asserted-by":"crossref","first-page":"4836","DOI":"10.4049\/jimmunol.1402071","article-title":"MF59 mediates its B cell adjuvanticity by promoting T follicular helper cells and thus germinal center responses in adult and early life","volume":"194","author":"Mastelic Gavillet","year":"2015","journal-title":"J Immunol"},{"key":"2021120808191529000_cei13004-bib-0038","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/j.1470-8744.1988.tb00012.x","article-title":"The requirement of lipids for the formation of immunostimulating complexes (iscoms)","volume":"10","author":"Lovgren","year":"1988","journal-title":"Biotechnol Appl Biochem"},{"key":"2021120808191529000_cei13004-bib-0039","doi-asserted-by":"crossref","first-page":"3640","DOI":"10.1016\/j.vaccine.2008.04.071","article-title":"Antibody and T-cell responses to a virosomal adjuvanted H9N2 avian influenza vaccine: impact of distinct additional adjuvants","volume":"26","author":"Radosevic","year":"2008","journal-title":"Vaccine"},{"key":"2021120808191529000_cei13004-bib-0040","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.4161\/hv.29583","article-title":"Matrix M(TM) adjuvanted virosomal H5N1 vaccine induces balanced Th1\/Th2 CD4(+) T cell responses in man","volume":"10","author":"Pedersen","year":"2014","journal-title":"Hum Vaccin Immunother"},{"key":"2021120808191529000_cei13004-bib-0041","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1016\/j.vaccine.2015.03.009","article-title":"Recombinant virus-like particles elicit protective immunity against avian influenza A(H7N9) virus infection in ferrets","volume":"33","author":"Liu","year":"2015","journal-title":"Vaccine"},{"key":"2021120808191529000_cei13004-bib-0042","author":"Study of Parenterally Administrated Adjuvanted Seasonal Influenza Vaccine in Healthy Elderly Volunteers"},{"key":"2021120808191529000_cei13004-bib-0043","author":"A(H7N9) VLP Antigen Dose-Ranging Study With Matrix-M1\u2122 Adjuvant"},{"key":"2021120808191529000_cei13004-bib-0044","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1586\/14760584.2016.1164046","article-title":"Influenza immunology evaluation and correlates of protection: a focus on vaccines","volume":"15","author":"Trombetta","year":"2016","journal-title":"Expert Rev Vaccines"},{"key":"2021120808191529000_cei13004-bib-0045","first-page":"145","article-title":"Enhancement of Th1 immune responses to recombinant influenza nucleoprotein by Ribi adjuvant","volume":"36","author":"Cargnelutti","year":"2013","journal-title":"New Microbiol"},{"key":"2021120808191529000_cei13004-bib-0046","doi-asserted-by":"crossref","first-page":"e61775","DOI":"10.1371\/journal.pone.0061775","article-title":"Influenza nucleoprotein delivered with aluminium salts protects mice from an influenza A virus that expresses an altered nucleoprotein sequence","volume":"8","author":"Macleod","year":"2013","journal-title":"PLOS ONE"},{"key":"2021120808191529000_cei13004-bib-0047","doi-asserted-by":"crossref","first-page":"10209","DOI":"10.1128\/JVI.01633-16","article-title":"Increased protein degradation improves influenza virus nucleoprotein-specific CD8+ T cell activation in vitro but not in C57BL\/6 mice","volume":"90","author":"Altenburg","year":"2016","journal-title":"J Virol"},{"key":"2021120808191529000_cei13004-bib-0048","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S1074-7613(00)80573-7","article-title":"Virus-specific CD8+ T cells in primary and secondary influenza pneumonia","volume":"8","author":"Flynn","year":"1998","journal-title":"Immunity"},{"key":"2021120808191529000_cei13004-bib-0049","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1586\/erv.11.25","article-title":"ISCOM technology-based Matrix M adjuvant: success in future vaccines relies on formulation","volume":"10","author":"Lovgren Bengtsson","year":"2011","journal-title":"Expert Rev Vaccines"},{"key":"2021120808191529000_cei13004-bib-0050","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1086\/517614","article-title":"Recombinant modified vaccinia virus Ankara-based vaccine induces protective immunity in mice against infection with influenza virus H5N1","volume":"195","author":"Kreijtz","year":"2007","journal-title":"J Infect Dis"},{"key":"2021120808191529000_cei13004-bib-0051","doi-asserted-by":"crossref","first-page":"925135","DOI":"10.1155\/2012\/925135","article-title":"CD4(+)T cells: differentiation and functions","volume":"2012","author":"Luckheeram","year":"2012","journal-title":"Clin Dev Immunol"},{"key":"2021120808191529000_cei13004-bib-0052","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1038\/srep01443","article-title":"Immunity against heterosubtypic influenza virus induced by adenovirus and MVA expressing nucleoprotein and matrix protein-1","volume":"3","author":"Lambe","year":"2013","journal-title":"Sci Rep"},{"key":"2021120808191529000_cei13004-bib-0053","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.vaccine.2013.12.030","article-title":"Matrix-M adjuvanted envelope protein vaccine protects against lethal lineage 1 and 2 West Nile virus infection in mice","volume":"32","author":"Magnusson","year":"2014","journal-title":"Vaccine"},{"key":"2021120808191529000_cei13004-bib-0054","doi-asserted-by":"crossref","first-page":"e112568","DOI":"10.1371\/journal.pone.0112568","article-title":"Vaccine-induced protection of rhesus macaques against plasma viremia after intradermal infection with a European lineage 1 strain of West Nile virus","volume":"9","author":"Verstrepen","year":"2014","journal-title":"PLOS ONE"},{"key":"2021120808191529000_cei13004-bib-0055","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1016\/j.vaccine.2016.02.033","article-title":"Matrix-M adjuvant enhances antibody, cellular and protective immune responses of a Zaire Ebola\/Makona virus glycoprotein (GP) nanoparticle vaccine in mice","volume":"34","author":"Bengtsson","year":"2016","journal-title":"Vaccine"},{"key":"2021120808191529000_cei13004-bib-0056","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/j.1600-0854.2005.00263.x","article-title":"An unconventional NLS is critical for the nuclear import of the influenza A virus nucleoprotein and ribonucleoprotein","volume":"6","author":"Cros","year":"2005","journal-title":"Traffic"},{"key":"2021120808191529000_cei13004-bib-0057","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1128\/JVI.01434-06","article-title":"Contributions of two nuclear localization signals of influenza A virus nucleoprotein to viral replication","volume":"81","author":"Ozawa","year":"2007","journal-title":"J Virol"},{"key":"2021120808191529000_cei13004-bib-0058","doi-asserted-by":"crossref","first-page":"38818","DOI":"10.1074\/jbc.M205547200","article-title":"Fusion proteins with COOH-terminal ubiquitin are stable and maintain dual functionality in vivo","volume":"277","author":"Qian","year":"2002","journal-title":"J Biol Chem"},{"key":"2021120808191529000_cei13004-bib-0059","doi-asserted-by":"crossref","first-page":"4168","DOI":"10.4049\/jimmunol.181.6.4168","article-title":"A novel role for non-neutralizing antibodies against nucleoprotein in facilitating resistance to influenza virus","volume":"181","author":"Carragher","year":"2008","journal-title":"J Immunol"},{"key":"2021120808191529000_cei13004-bib-0060","doi-asserted-by":"crossref","first-page":"4331","DOI":"10.4049\/jimmunol.1003057","article-title":"Contributions of antinucleoprotein IgG to heterosubtypic immunity against influenza virus","volume":"186","author":"LaMere","year":"2011","journal-title":"J Immunol"},{"key":"2021120808191529000_cei13004-bib-0061","doi-asserted-by":"crossref","first-page":"5027","DOI":"10.1128\/JVI.00150-11","article-title":"Regulation of antinucleoprotein IgG by systemic vaccination and its effect on influenza virus clearance","volume":"85","author":"Lamere","year":"2011","journal-title":"J Virol"},{"key":"2021120808191529000_cei13004-bib-0062","first-page":"417","article-title":"Influenza nucleoprotein-specific cytotoxic T-cell clones are protective in vivo","volume":"58","author":"Taylor","year":"1986","journal-title":"Immunology"},{"key":"2021120808191529000_cei13004-bib-0063","doi-asserted-by":"crossref","first-page":"6512","DOI":"10.1016\/j.vaccine.2009.08.053","article-title":"Vaccination focusing immunity on conserved antigens protects mice and ferrets against virulent H1N1 and H5N1 influenza A viruses","volume":"27","author":"Price","year":"2009","journal-title":"Vaccine"},{"key":"2021120808191529000_cei13004-bib-0064","doi-asserted-by":"crossref","first-page":"e11400","DOI":"10.1371\/journal.pone.0011400","article-title":"Modified vaccinia virus Ankara exerts potent immune modulatory activities in a murine model","volume":"5","author":"Norder","year":"2010","journal-title":"PLOS ONE"},{"key":"2021120808191529000_cei13004-bib-0065","doi-asserted-by":"crossref","first-page":"e1000480","DOI":"10.1371\/journal.ppat.1000480","article-title":"Innate immune sensing of modified vaccinia virus Ankara (MVA) is mediated by TLR2\u2013TLR6, MDA-5 and the NALP3 inflammasome","volume":"5","author":"Delaloye","year":"2009","journal-title":"PLOS Pathog"},{"key":"2021120808191529000_cei13004-bib-0066","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/BF00914308","article-title":"Inflammatory response and antigen localization following immunization with influenza virus ISCOMs","volume":"13","author":"Watson","year":"1989","journal-title":"Inflammation"},{"key":"2021120808191529000_cei13004-bib-0067","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/S0264-410X(96)00288-5","article-title":"Kinetics, localization and cytokine profile of T cell responses to immune stimulating complexes (iscoms) containing human influenza virus envelope glycoproteins","volume":"15","author":"Sjolander","year":"1997","journal-title":"Vaccine"},{"key":"2021120808191529000_cei13004-bib-0068","doi-asserted-by":"crossref","first-page":"11925","DOI":"10.1128\/JVI.00903-07","article-title":"Cross-priming of cytotoxic T cells dictates antigen requisites for modified vaccinia virus Ankara vector vaccines","volume":"81","author":"Gasteiger","year":"2007","journal-title":"J Virol"},{"key":"2021120808191529000_cei13004-bib-0069","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.coi.2010.04.002","article-title":"Designing CD8+ T cell vaccines: it's not rocket science (yet)","volume":"22","author":"Yewdell","year":"2010","journal-title":"Curr Opin Immunol"},{"key":"2021120808191529000_cei13004-bib-0070","doi-asserted-by":"crossref","first-page":"3835","DOI":"10.4049\/jimmunol.1602122","article-title":"Varied role of ubiquitylation in generating MHC class I peptide ligands","volume":"198","author":"Wei","year":"2017","journal-title":"J Immunol"}],"container-title":["Clinical and Experimental Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fcei.13004","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/190\/1\/19\/41644029\/cei13004.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/190\/1\/19\/41644029\/cei13004.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T16:25:34Z","timestamp":1641054334000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cei\/article\/190\/1\/19\/6412374"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,24]]},"references-count":70,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,7,24]]},"published-print":{"date-parts":[[2017,9,7]]}},"URL":"https:\/\/doi.org\/10.1111\/cei.13004","relation":{},"ISSN":["0009-9104","1365-2249"],"issn-type":[{"value":"0009-9104","type":"print"},{"value":"1365-2249","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,10]]},"published":{"date-parts":[[2017,7,24]]}}}